Cancer Survivors3D-BONENCT07022262
Virtual Exercise Training and Its Impact on Bone Compartments in Adult Survivors of Childhood Cancer
A study testing Progressive resistance training plus impact loading in people with Cancer Survivors, run by Universidad de Granada at 1 site in Spain.
Trial summary
Childhood cancer is a rare disease but a significant cause of death in children and adolescents. The incidence of childhood cancer is 1case per 300 cases of adult cancer, but surviving to it has important sequels. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Cancer Survivors
- What is being tested?
- Progressive resistance training plus impact loading
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 116 participants
- Where
- 1 siteSpain
- Study dates
- May 2026to Aug 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Prior diagnosis of pediatric cancer and history of receiving treatment (radiation therapy and/or chemotherapy).
- 18-55 years of age at recruitment
Who cannot join
- Participation in another research study simultaneously.
- Not currently receiving cancer treatment.
- Previous diagnosed anorexia/bulimia, known pregnancy, known alcohol or drug abuse.
- Requiring chronic oral glucocorticoid therapy.
- Having an injury that may affect daily life activities and can be aggravated by exercise.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site
Sport and Health University Research Institute (iMUDS), Technological Health Park, University of Granada
Granada, Andalusia, 18007
Esther Ubago Guisado, Ramón y Cajal researcher, +34 958246644, estherug@ugr.es
Luis Gracia Marco, Senior Lecturer, +34 958244363, lgracia@ugr.es
About this study
Official title: 3D-BONE: Virtual Exercise Training and Its Impact on Cortical and Trabecular Bone Compartments in Adult Survivors of Childhood Cancer: a Peripheral Quantitative Computed Tomography (pQCT) Study
Childhood cancer is a rare disease but a significant cause of death in children and adolescents. The incidence of childhood cancer is 1case per 300 cases of adult cancer, but surviving to it has important sequels. Endocrine dysfunction represents one of the most common issues in paediatric cancer survivors and impairs bone mineral density later in life. Some forms of exercise have been recommended to preserve bone health in healthy adults; however, its effect has not been properly studied yet in adult survivors of paediatric cancer using cutting-edge technologies, such as peripheral quantitative computed tomography (pQCT). As general aim, the 3D-BONE study will assess for the first time the effect of a live and online exercise programme on bone parameters and bone metabolism in adult survivors of paediatric cancer. This multicenter randomized controlled trial will be performed in three Andalusian provinces (Granada, Cordoba and Almeria). A minimum of 116 adult survivors of paediatric cancer aged 18 to 55 years will be recruited following the inclusion and exclusion criteria. They will be randomized (based on sex and age) into an INTERVENTION (n=58) or CONTROL group (n=58). The intervention group will receive a 6-month live and online exercise program based on progressive resistance and impact loading training that will be delivered by qualified professionals using a telehealth mobile app (3D-BONE app). Moreover, behaviour change techniques will be implemented in order to increase motivation and adherence to the program. This group will also receive diet counselling on calcium and vitamin so the difference between the groups is the exercise programme. Participants will be assessed before and after the intervention at the facilities of the Sport and Health University Research Institute (iMUDS) of the University of Granada. An in-depth analysis of bone parameters will be carried out using cutting-edge technologies, such as the pQCT (to analyse cortical and trabecular bone in 3 dimensions), dual-energy X-ray absorptiometry (DXA), hip and lumbar spine geometry outcomes. Moreover, a complete blood count will be obtained and markers of bone metabolism will be measured (B-CTX, PINP), including novel markers such as sclerostin and irisin which have recently been linked to human bone. Data will also be collected in anthropometry and body composition to obtain cardiovascular risk factors, sarcopenia and physiologic frailty risk factors, mental health, health-related quality of life and objective measures of physical activity and fitness. This will ensure obtaining novel, precise and strong data in this population.
- Conditions
- Cancer Survivors
- Being tested
- Progressive resistance training plus impact loading
- Keywords
- cancer survivors, childhood cancer, exercise, bone health, physical fitness, sarcopenia, physiological frailty, mental health, health-related quality of life, pQCT
- Medical subject headings
- Neoplasms, Motor Activity, Sarcopenia, Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Progressive resistance training plus impact loadingBehavioural
The intervention will be performed 3 days a week (Monday, Tuesday and Thursday [group 1] and Monday, Wednesday and Thursday [group 2]), following previous studies. Each section will last 45 minutes, comprising 10 minutes of warm-up, 20 minutes of resistance training, 10 minutes of impact exercises, and 5 minutes of cool down. There will always be a minimum of 24-hour interval between exercise sessions, and an extra training day (Friday) will be available if participants miss a training day in the respective week.
The exercise periodisation will be composed by 3 phases (phase 1, phase 2 and phase 3). Across phases, training volume will vary and a progressively increase in exercise intensity will be applied in each phase. The three phases of the study will consist of 8 weeks, and within each phase the participants will perform six different training sessions.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | 6-months of live and online progressive resistance training plus impact loading + dietary counselling on calcium and vitamin D. Receives: Behavioral: Progressive resistance training plus impact loading |
| Control group | No intervention | Dietary counselling on calcium and vitamin D. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Cortical and Trabecular Volumetric Bone Mineral Density (pQCT)
Cortical and trabecular BMD will be measured at tibia and radius using pQCT (mg/cm³).
Measured: Baseline and 6 months
Change in Cortical Bone Thickness (pQCT)
Cortical bone thickness at tibia and radius (mm) will be derived from pQCT images.
Measured: Baseline and 6 months
Change in Periosteal and Endocortical Circumference (pQCT)
Periosteal and endocortical circumference at tibia and radius will be measured via pQCT (mm)
Measured: Baseline and 6 months
Change in Cross-Sectional Moment of Inertia-CSMI (pQCT)
CSMI at tibia and radius will be calculated to assess structural bone strength (mm⁴).
Measured: Baseline and 6 months
Change in Bone strehgth indices (pQCT)
Bone strehgth indices at tibia and radius will be obtained from pQCT images
Measured: Baseline and 6 months
Change in Bone Mineral Content (DXA)
BMC will be assessed using DXA at whole-body and regional sites (g)
Measured: Baseline and 6 months
Change in Areal Bone Mineral Density (DXA)
Areal BMD will be measured with DXA at whole-body and regional sites (g/cm²)
Measured: Baseline and 6 months
Change in Cross-Sectional Area (DXA-HSA)
Derived from hip structural analysis (mm²).
Measured: Baseline and 6 months
Change in Section Modulus (DXA-HSA)
Indicates bone strength; calculated from HSA (mm³).
Measured: Baseline and 6 months
Change in Cross-Sectional Moment of Inertia (DXA-HSA)
Assesses resistance to bending forces (mm⁴).
Measured: Baseline and 6 months
Change in Trabecular Bone Score (TBS)
Lumbar spine texture will be assessed using TBS (TBS index).
Measured: Baseline and 6 months
Change in Serum Lipid Profile
Cholesterol, triglycerides, HDL, LDL levels (mg/dL).
Measured: Baseline and 6 months
Change in Total bilirubin
mg/dL
Measured: Baseline and 6 months
Change in Calcium
mg/dL
Measured: Baseline and 6 months
Change in Creatinine
mg/dL
Measured: Baseline and 6 months
Change in Phosphorus
mg/dL
Measured: Baseline and 6 months
Change in Glucose
mg/dL
Measured: Baseline and 6 months
Change in Magnesium
mg/dL
Measured: Baseline and 6 months
Change in Uric acid
mg/dL
Measured: Baseline and 6 months
Change in ALT/GPT
U/L
Measured: Baseline and 6 months
Change in Na/K/Cl
mEq/L
Measured: Baseline and 6 months
Change in Albumin
g/dL
Measured: Baseline and 6 months
Change in Total protein
g/dL
Measured: Baseline and 6 months
Change in Serum 25(OH) Vitamin D
ng/mL
Measured: Baseline and 6 months
Change in Alkaline phosphatase
U/L
Measured: Baseline and 6 months
Change in Bone specific alkaline phosphatase
ng/mL
Measured: Baseline and 6 months
Change in Glycosylated hemoglobin
mmol/mol
Measured: Baseline and 6 months
Change in Parathyrin
pg/mL
Measured: Baseline and 6 months
Change in Thyrotropin
µUI/mL
Measured: Baseline and 6 months
Change in Gamma-glutamyl transferase
U/L
Measured: Baseline and 6 months
Change in β-CTX (Serum)
Marker of bone resorption (ng/mL)
Measured: Baseline and 6 months
Change in PINP (Serum)
Marker of bone formation (ng/mL)
Measured: Baseline and 6 months
Change in Irisin (Serum)
ng/mL
Measured: Baseline and 6 months
Change in Sclerostin (Serum)
ng/mL
Measured: Baseline and 6 months
Secondary outcomes (27)
Change in Body Mass
Measured with electronic scale (kg).
Measured: Baseline and 6 months
Change in Height
Measured with stadiometer (cm).
Measured: Baseline and 6 months
Change in Body Mass Index (BMI)
Calculated as kg/m².
Measured: Baseline and 6 months
Change in Blood Pressure
Systolic and diastolic pressure measured in mmHg.
Measured: Baseline and 6 months
Change in body circumferences
Waist, hip and neck circumferences measured in cm.
Measured: Baseline and 6 months
Change in Lean Soft Tissue Mass (DXA)
Assessed at whole-body using DXA (g).
Measured: Baseline and 6 months
Change in Fat Mass (DXA)
Assessed at whole-body using DXA (kg).
Measured: Baseline and 6 months
Change in Body Fat Percentage (DXA)
Assessed at whole-body using DXA (%).
Measured: Baseline and 6 months
Change in 6-Minute Walk Test
Distance walked in 6 minutes (meters).
Measured: Baseline and 6 months
Change in Squat Jump Test
Height achieved in the test (cm).
Measured: Baseline and 6 months
Change in Handgrip Strength Test
Maximal grip force (kg).
Measured: Baseline and 6 months
Change in Standing Long Jump Test
Distance achieved in the test (cm).
Measured: Baseline and 6 months
Change in 5 Times Sit-to-Stand Test
Time to complete 5 repetitions (seconds)
Measured: Baseline and 6 months
Change in 4-m Gait Speed Test
Time to walk 4 meters (seconds)
Measured: Baseline and 6 months
Change in Self-Reported Fitness (IFIS)
Perceived fitness using IFIS questionnaire.
Measured: Baseline and 6 months
Change in Sarcopenia Classification (EWGSOP2)
Sarcopenia will be classified as no, probable, or confirmed based on grip strength, sit-to-stand time, and appendicular lean mass by DXA. Categorical (no/probable/confirmed).
Measured: Baseline and 6 months
Change in Frailty Status
Frailty will be assessed using five criteria: low muscle mass, fatigue, low physical activity, slowness, and weakness. Categorical (frail/non-frail).
Measured: Baseline and 6 months
Change in Physical Activity and Sedentarism (Accelerometer)
Measured over 7 consecutive days using ActiGraph (counts per minute).
Measured: Baseline and 6 months
Change in Self-Reported Physical Activity (IPAQ)
Activity levels using the IPAQ (MET-min/week)
Measured: Baseline and 6 months
Change in Bone-Specific Physical Activity (BPAQ)
Scored from the BPAQ questionnaire (BPAQ score)
Measured: Baseline and 6 months
Change in Calcium Intake
Estimated using validated short calcium questionnaire (mg/day).
Measured: Baseline and 6 months
Change in Vitamin D Intake
Estimated from dietary questionnaire (IU/day).
Measured: Baseline and 6 months
Change in Mediterranean Diet Adherence
Calculated from validated adherence questionnaire (Score 0-14)
Measured: Baseline and 6 months
Change in Quality of Life
HRQoL from the SF-36 questionnaire (0-100 scale).
Measured: Baseline and 6 months
Change in Anxiety and Depression (HADS)
Anxiety and depression score from HADS (Score 0-21)
Measured: Baseline and 6 months
Change in Self-Esteem (Rosenberg Scale)
Assessed using Rosenberg Self-Esteem Scale (Score 0-30)
Measured: Baseline and 6 months
Change in Perceived Stress (PSS)
Assessed via Perceived Stress Scale (Score 0-40).
Measured: Baseline and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jun 2025
- Study startMay 2026 (estimated)
- Primary completionAug 2027 (estimated)
- Study completionAug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer SurvivorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 116 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad de Granada
- Sponsor type
- University, hospital or other
- Collaborators
- Loyola University, University of Thessaly, Hospital Materno-Infantil Torrecárdenas de Almería, Hospital Universitario Reina Sofia de Cordoba, University Hospital Virgen de las Nieves
- Responsible party
- Principal investigator, Esther Ubago Guisado, Universidad de Granada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07022262
- Sponsor's protocol ID
- Universidad de Granada
- Other IDs
- PID2023-150311OB-I00
- Acronym
- 3D-BONE
- Status last verified
- Apr 2026
- First submitted
- 26 May 2025
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data files including IPD and corresponding data dictionaries will be shared under restricted access and upon reasonable request (E Ubago-Guisado or L Gracia-Marco) due to privacy issue and GDPR regulations. In principle, all collected IPD will be available for sharing under the "as open as possible, as closed as necessary" principle. The shared data files will be pseudonymized, only include participants who provided informed consent for sharing, and sharing is only possible when the data is used for research purposes. This is stated at the informed consent files that the participants signed when they agree to participate.
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 3D-BONE: Virtual Exercise Training and Its Impact on Cortical and Trabecular Bone Compartments in Adult Survivors of Childhood Cancer: a Peripheral Quantitative Computed Tomography (pQCT) Study
- ClinicalTrials.gov ID
- NCT07022262
- Acronym / sponsor ID
- 3D-BONE / Universidad de Granada
- Conditions
- Cancer Survivors
- Keywords
- cancer survivors, childhood cancer, exercise, bone health, physical fitness, sarcopenia, physiological frailty, mental health
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 116 participants (estimated)
- Lead sponsor
- Universidad de GranadaUniversity, hospital or other
- Collaborators
- Loyola University, University of Thessaly, Hospital Materno-Infantil Torrecárdenas de Almería, Hospital Universitario Reina Sofia de Cordoba, University Hospital Virgen de las Nieves
- Study start
- May 2026 (estimated)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Aug 2028 (estimated)
- First posted
- 15 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Childhood cancer is a rare disease but a significant cause of death in children and adolescents. The incidence of childhood cancer is 1case per 300 cases of adult cancer, but surviving to it has important sequels. Endocrine dysfunction represents one of the most common issues in paediatric cancer survivors and impairs bone mineral density later in life. Some forms of exercise have been recommended to preserve bone health in healthy adults; however, its effect has not been properly studied yet in adult survivors of paediatric cancer using cutting-edge technologies, such as peripheral quantitative computed tomography (pQCT). As general aim, the 3D-BONE study will assess for the first time the effect of a live and online exercise programme on bone parameters and bone metabolism in adult survivors of paediatric cancer. This multicenter randomized controlled trial will be performed in three Andalusian provinces (Granada, Cordoba and Almeria). A minimum of 116 adult survivors of paediatric cancer aged 18 to 55 years will be recruited following the inclusion and exclusion criteria. They will be randomized (based on sex and age) into an INTERVENTION (n=58) or CONTROL group (n=58). The intervention group will receive a 6-month live and online exercise program based on progressive resistance and impact loading training that will be delivered by qualified professionals using a telehealth mobile app (3D-BONE app). Moreover, behaviour change techniques will be implemented in order to increase motivation and adherence to the program. This group will also receive diet counselling on calcium and vitamin so the difference between the groups is the exercise programme. Participants will be assessed before and after the intervention at the facilities of the Sport and Health University Research Institute (iMUDS) of the University of Granada. An in-depth analysis of bone parameters will be carried out using cutting-edge technologies, such as the pQCT (to analyse cortical and trabecular bone in 3 dimensions), dual-energy X-ray absorptiometry (DXA), hip and lumbar spine geometry outcomes. Moreover, a complete blood count will be obtained and markers of bone metabolism will be measured (B-CTX, PINP), including novel markers such as sclerostin and irisin which have recently been linked to human bone. Data will also be collected in anthropometry and body composition to obtain cardiovascular risk factors, sarcopenia and physiologic frailty risk factors, mental health, health-related quality of life and objective measures of physical activity and fitness. This will ensure obtaining novel, precise and strong data in this population.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Behavioral: Progressive resistance training plus impact loading6-months of live and online progressive resistance training plus impact loading + dietary counselling on calcium and vitamin D. |
| Control group | No intervention | –Dietary counselling on calcium and vitamin D. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Prior diagnosis of pediatric cancer and history of receiving treatment (radiation therapy and/or chemotherapy).
- 18-55 years of age at recruitment
Key exclusion criteria (5 listed)
- Participation in another research study simultaneously.
- Not currently receiving cancer treatment.
- Previous diagnosed anorexia/bulimia, known pregnancy, known alcohol or drug abuse.
- Requiring chronic oral glucocorticoid therapy.
- Having an injury that may affect daily life activities and can be aggravated by exercise.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Progressive resistance training plus impact loadingThe intervention will be performed 3 days a week (Monday, Tuesday and Thursday [group 1] and Monday, Wednesday and Thursday [group 2]), following previous studies. Each section will last 45 minutes, comprising 10 minutes of warm-up, 20 minutes of resistance training, 10 minutes of impact exercises, and 5 minutes of cool down. There will always be a minimum of 24-hour interval between exercise sessions, and an extra training day (Friday) will be available if participants miss a training day in the respective week. The exercise periodisation will be composed by 3 phases (phase 1, phase 2 and phase 3). Across phases, training volume will vary and a progressively increase in exercise intensity will be applied in each phase. The three phases of the study will consist of 8 weeks, and within each phase the participants will perform six different training sessions. | Behavioural | Intervention group |
Primary outcome
Change in Cortical and Trabecular Volumetric Bone Mineral Density (pQCT)
Time frame: Baseline and 6 months
Cortical and trabecular BMD will be measured at tibia and radius using pQCT (mg/cm³).
Change in Cortical Bone Thickness (pQCT)
Time frame: Baseline and 6 months
Cortical bone thickness at tibia and radius (mm) will be derived from pQCT images.
Change in Periosteal and Endocortical Circumference (pQCT)
Time frame: Baseline and 6 months
Periosteal and endocortical circumference at tibia and radius will be measured via pQCT (mm)
Change in Cross-Sectional Moment of Inertia-CSMI (pQCT)
Time frame: Baseline and 6 months
CSMI at tibia and radius will be calculated to assess structural bone strength (mm⁴).
Change in Bone strehgth indices (pQCT)
Time frame: Baseline and 6 months
Bone strehgth indices at tibia and radius will be obtained from pQCT images
Change in Bone Mineral Content (DXA)
Time frame: Baseline and 6 months
BMC will be assessed using DXA at whole-body and regional sites (g)
Change in Areal Bone Mineral Density (DXA)
Time frame: Baseline and 6 months
Areal BMD will be measured with DXA at whole-body and regional sites (g/cm²)
Change in Cross-Sectional Area (DXA-HSA)
Time frame: Baseline and 6 months
Derived from hip structural analysis (mm²).
Change in Section Modulus (DXA-HSA)
Time frame: Baseline and 6 months
Indicates bone strength; calculated from HSA (mm³).
Change in Cross-Sectional Moment of Inertia (DXA-HSA)
Time frame: Baseline and 6 months
Assesses resistance to bending forces (mm⁴).
Change in Trabecular Bone Score (TBS)
Time frame: Baseline and 6 months
Lumbar spine texture will be assessed using TBS (TBS index).
Change in Serum Lipid Profile
Time frame: Baseline and 6 months
Cholesterol, triglycerides, HDL, LDL levels (mg/dL).
Change in Total bilirubin
Time frame: Baseline and 6 months
mg/dL
Change in Calcium
Time frame: Baseline and 6 months
mg/dL
Change in Creatinine
Time frame: Baseline and 6 months
mg/dL
Change in Phosphorus
Time frame: Baseline and 6 months
mg/dL
Change in Glucose
Time frame: Baseline and 6 months
mg/dL
Change in Magnesium
Time frame: Baseline and 6 months
mg/dL
Change in Uric acid
Time frame: Baseline and 6 months
mg/dL
Change in ALT/GPT
Time frame: Baseline and 6 months
U/L
Change in Na/K/Cl
Time frame: Baseline and 6 months
mEq/L
Change in Albumin
Time frame: Baseline and 6 months
g/dL
Change in Total protein
Time frame: Baseline and 6 months
g/dL
Change in Serum 25(OH) Vitamin D
Time frame: Baseline and 6 months
ng/mL
Change in Alkaline phosphatase
Time frame: Baseline and 6 months
U/L
Change in Bone specific alkaline phosphatase
Time frame: Baseline and 6 months
ng/mL
Change in Glycosylated hemoglobin
Time frame: Baseline and 6 months
mmol/mol
Change in Parathyrin
Time frame: Baseline and 6 months
pg/mL
Change in Thyrotropin
Time frame: Baseline and 6 months
µUI/mL
Change in Gamma-glutamyl transferase
Time frame: Baseline and 6 months
U/L
Change in β-CTX (Serum)
Time frame: Baseline and 6 months
Marker of bone resorption (ng/mL)
Change in PINP (Serum)
Time frame: Baseline and 6 months
Marker of bone formation (ng/mL)
Change in Irisin (Serum)
Time frame: Baseline and 6 months
ng/mL
Change in Sclerostin (Serum)
Time frame: Baseline and 6 months
ng/mL
27 secondary outcomes
Change in Body Mass
Time frame: Baseline and 6 months
Change in Height
Time frame: Baseline and 6 months
Change in Body Mass Index (BMI)
Time frame: Baseline and 6 months
Change in Blood Pressure
Time frame: Baseline and 6 months
Change in body circumferences
Time frame: Baseline and 6 months
Change in Lean Soft Tissue Mass (DXA)
Time frame: Baseline and 6 months
Change in Fat Mass (DXA)
Time frame: Baseline and 6 months
Change in Body Fat Percentage (DXA)
Time frame: Baseline and 6 months
Change in 6-Minute Walk Test
Time frame: Baseline and 6 months
Change in Squat Jump Test
Time frame: Baseline and 6 months
Change in Handgrip Strength Test
Time frame: Baseline and 6 months
Change in Standing Long Jump Test
Time frame: Baseline and 6 months
Change in 5 Times Sit-to-Stand Test
Time frame: Baseline and 6 months
Change in 4-m Gait Speed Test
Time frame: Baseline and 6 months
Change in Self-Reported Fitness (IFIS)
Time frame: Baseline and 6 months
Change in Sarcopenia Classification (EWGSOP2)
Time frame: Baseline and 6 months
Change in Frailty Status
Time frame: Baseline and 6 months
Change in Physical Activity and Sedentarism (Accelerometer)
Time frame: Baseline and 6 months
Change in Self-Reported Physical Activity (IPAQ)
Time frame: Baseline and 6 months
Change in Bone-Specific Physical Activity (BPAQ)
Time frame: Baseline and 6 months
Change in Calcium Intake
Time frame: Baseline and 6 months
Change in Vitamin D Intake
Time frame: Baseline and 6 months
Change in Mediterranean Diet Adherence
Time frame: Baseline and 6 months
Change in Quality of Life
Time frame: Baseline and 6 months
Change in Anxiety and Depression (HADS)
Time frame: Baseline and 6 months
Change in Self-Esteem (Rosenberg Scale)
Time frame: Baseline and 6 months
Change in Perceived Stress (PSS)
Time frame: Baseline and 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Individual participant dataSharing planned: Yes. Data files including IPD and corresponding data dictionaries will be shared under restricted access and upon reasonable request (E Ubago-Guisado or L Gracia-Marco) due to privacy issue and GDPR regulations. In principle, all collected IPD will be available for sharing under the "as open as possible, as closed as necessary" principle. The shared data files will be pseudonymized, only include participants who provided informed consent for sharing, and sharing is only possible when the data is used for research purposes. This is stated at the informed consent files that the participants signed when they agree to participate.
Related trials for Cancer Survivors
Recruiting
Developing a Scalable Tobacco Cessation Program for Cancer Survivors and Caregivers
Nicotine Use, Tobacco Use
Recruiting
Pilot SMART of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors
Breast Cancer
Active, not recruiting
Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Active, not recruiting
Electroacupuncture for the Management of Symptom Clusters in Cancer Patients and Survivors
Cancer
Active, not recruiting
Dance Study for Post-surgical Pain in Breast Cancer Survivors
Breast Cancer, Survivorship
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Progressive resistance training plus impact loading in people with Cancer Survivors, run by Universidad de Granada at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Esther Ubago Guisado, Ramón y Cajal researcher (+34 958246644, estherug@ugr.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Cortical and Trabecular Volumetric Bone Mineral Density (pQCT) (time frame: Baseline and 6 months). The study lists 34 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.